secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0000950170-24-091745
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma Q2 net loss $12.5M; neffy PDUFA Oct 2; cash $218.7M
--------------------------------------------------------------

- Cash, equivalents and short-term investments $218.7M as of June 30, 2024, providing at least three years of operating runway.
- Net loss $12.5M vs $17.4M in Q2 2023; R&D $6.9M, G&A $8.9M.
- neffy NDA under FDA review; draft physician labeling received; PDUFA target action date October 2, 2024.
- EURneffy received CHMP positive opinion; formal EU marketing authorization expected Q3 2024.
- Phase 2b outpatient study of neffy for urticaria on track to start dosing in Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000095017024091745/0000950170-24-091745-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000095017024091745/spry-20240806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-091745

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer